secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-09-15T12:05:07+00:00
Accession:  0001193125-26-391358
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals appoints Susan Kozauer as Chief Medical Officer; $515k base, NOVA-2 readout H1 2027
--------------------------------------------------------------------------------

- Appointed Susan G. Kozauer, M.D. as CMO effective Sept 14, 2026; previously SVP at Centessa and VP at Intra-Cellular.
- Compensation: $515k annual base salary, 40% target bonus, $150k sign-on bonus, and 200,000-share option vesting over 4 years.
- CEO Heather Turner cites Kozauer's expertise as pivotal for Phase 3 NOVA-2 topline results in schizophrenia expected H1 2027.
- Kozauer led clinical development of CAPLYTA across schizophrenia, bipolar disorder, and MDD, resulting in multiple FDA approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/0001193125-26-391358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526391358/d157620d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-391358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer